InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,537.02
(
0.51%
)
US TECH 100
19,641.60
(
0.83%
)
Dow Jones
39,308.00
(
-0.06%
)
Brent Oil
87.33
(
0.48%
)
Bitcoin
58,009.36
(
-3.58%
)
Post# of 252484
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

poorgradstudent

Send PM Follow Ignore
Followers 73
Posts 3426
Boards Moderated 1
Alias Born 04/28/2004

poorgradstudent

Re: RockRat post# 199334

Thursday, 01/28/2016 2:50:25 AM

Thursday, January 28, 2016 2:50:25 AM

Post# of 252484
TRIL / Fluorinov:

Interesting to see a modest capitalization company buy someone else out.

Have to admit though that they're in tough with many of these projects. BET has plenty of competition, granted none are approved. The oral proteasome inhibitor is competition with at least one approved (ixazomib) and one investigational (oprozomib) competitor.

Do you think they're going to finance and spend money on these or is it a measured bet that they can out-license these for a cumulative up-front that outpaces the purchase price?
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up